ChitogenX Inc. CHNXF
0.01 USD 0.00 (+0.00%)
Regular-session close
0.0011 Day range 0.0013
0.0011 52-week range 0.00755
- YTD
- 0.00%
- 1 year
- +586.36%
News
proactiveinvestors.com ChitogenX ends 3Q with improved financial outlook; key milestones achieved ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) provided highlights for its third quarter of fiscal year 2024, which included the reduction of operating losses by 73% fiscal year to date compared with the…
proactiveinvestors.com ChitogenX demonstrates ORTHO-R efficacy and osteoarthritis protection in large animal meniscal repair study ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors that its proprietary chitosan/platelet-rich plasma (PRP)-based biopolymer matrix, ORTHO-R, has successfully demonstrated protection from joint…
proactiveinvestors.com ChitogenX targets multi-billion dollar burn and skin repair market ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors it has launched a new development program targeting significant unmet medical needs in the multi-billion dollar burn and skin repair market. Proof…
prnewswire.com CHITOGENX LAUNCHES BURN AND SKIN REPAIR DEVELOPMENT PROGRAM Significant unmet medical needs in US $19B burn and skin defects market New patent in US and Canada supports ChitogenX' proprietary chitosan-based biopolymer as ideal combination with cellular…
proactiveinvestors.com ChitogenX ends 2Q with stronger balance sheet as it advances its flagship ORTHO-R platform ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors that it made significant progress in deleveraging its balance sheet and improving its working capital as it continued to advance its ORTHO-R…
proactiveinvestors.com ChitogenX receives notice of allowance for key patent in the US and Canada ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors it has received a notice of allowance for a key patent in the US and Canada. The company noted that the patent confers protection for usage of the…
proactiveinvestors.com ChitogenX concludes enrolment for its US Phase I/II rotator cuff tear repair clinical trial ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has concluded the enrolment of 20 subjects in its US multi-site rotator cuff tear repair Phase I/II clinical trial entitled “A Blinded, Randomized…
proactiveinvestors.com ChitogenX reports first quarter results, highlights milestone in rotator cuff repair Phase I/II trial ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has noted that patient recruitment for its rotator cuff repair Phase I/II trial reached an important milestone in the first quarter to April 30, 2023, while its…
proactiveinvestors.com ChitogenX pursuing new strategic development partnerships ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has partnered with Bruder Consulting & Venture Group (BCVG) as its exclusive advisory firm for the pursuit of new strategic development partnerships. The…
proactiveinvestors.com ChitogenX highlights milestones achieved in fiscal year ChitogenX Inc has reported its financial results for the fourth quarter and fiscal year ended January 31, 2023, highlighting some milestones achieved during the period. The company successfully…
proactiveinvestors.com ChitogenX raises $3.9M to advance tissue repair research ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has closed its amended non-brokered private placement offering for gross proceeds of $3.86 million. The company said the funds would be used to complete…
proactiveinvestors.com ChitogenX announces non-brokered private placement for gross proceeds of $2.5M ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has announced a non-brokered private placement offering of 12,500,000 units at a price of $0.20 each for gross proceeds of $2.5 million. The Montreal-based…
proactiveinvestors.com ChitogenX obtains $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has obtained, in partnership with Polytechnique Montréal, a $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (NSERC)…
proactiveinvestors.com ChitogenX confirms soft-tissue residency properties of its chitosan/PRP-based biopolymer matrix ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has successfully confirmed soft-tissue residency properties of its chitosan/platelet-rich plasma (PRP)-based biopolymer matrix, ORTHO-R, in a…
proactiveinvestors.com Chitogenx maintains ‘Outperform' rating as Noble Capital Corp analysts raise price target ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) should be able to raise the full C$6.1 million in gross proceeds it is targeting in a two-part equity raise as it progresses its trials for its ORTHO-R Rotator…
proactiveinvestors.com ChitogenX looks to raise up to $6.10 million from private placements ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has announced a best efforts private placement of 19,333,333 units of the company at a price of $0.225 per unit for gross proceeds of up to $4.35 million,…
proactiveinvestors.ca ChitogenX earns repeat ‘Outperform' rating from Noble Capital on above-average market opportunity in the regenerative medicine sector ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF)'s chitosan biopolymer technology has a myriad of opportunities according to analysts at Noble Capital analysts who have reiterated their ‘Outperform' rating for…
proactiveinvestors.com ChitogenX pursues sales of chitosan as a new revenue initiative in fiscal 3Q and restructures balance sheet ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has posted financial results for its fiscal third quarter which showed that it is pursuing sales of medical-grade chitosan as a new near-term commercial revenue…
proactiveinvestors.ca ChitogenX successfully completes the initial portion of its US Phase I/II rotator cuff repair clinical trial ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) announced that it has successfully completed the initial portion of its US Phase I/II ORTHO-R rotator cuff tear repair clinical trial requiring staggered…
proactiveinvestors.com ChitogenX announces partnership with California Medical Innovations Institute ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has announced a partnership with the California Medical Innovations Institute (CALMI2), a non-profit organization exclusively for research, scientific and…